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BACKGROUND
Chronic obstructive pulmonary disease (COPD) is thought to result from an ac-
celerated decline in forced expiratory volume in 1 second (FEV1) over time. Yet it 
is possible that a normal decline in FEV1 could also lead to COPD in persons whose 
maximally attained FEV1 is less than population norms.
METHODS
We stratified participants in three independent cohorts (the Framingham Off-
spring Cohort, the Copenhagen City Heart Study, and the Lovelace Smokers Co-
hort) according to lung function (FEV1 ≥80% or <80% of the predicted value) at 
cohort inception (mean age of patients, approximately 40 years) and the presence 
or absence of COPD at the last study visit. We then determined the rate of decline 
in FEV1 over time among the participants according to their FEV1 at cohort incep-
tion and COPD status at study end.
RESULTS
Among 657 persons who had an FEV1 of less than 80% of the predicted value 
before 40 years of age, 174 (26%) had COPD after 22 years of observation, where-
as among 2207 persons who had a baseline FEV1 of at least 80% of the predicted 
value before 40 years of age, 158 (7%) had COPD after 22 years of observation 
(P<0.001). Approximately half the 332 persons with COPD at the end of the obser-
vation period had had a normal FEV1 before 40 years of age and had a rapid decline 
in FEV1 thereafter, with a mean (±SD) decline of 53±21 ml per year. The remaining 
half had had a low FEV1 in early adulthood and a subsequent mean decline in FEV1 
of 27±18 ml per year (P<0.001), despite similar smoking exposure.
CONCLUSIONS
Our study suggests that low FEV1 in early adulthood is important in the genesis of 
COPD and that accelerated decline in FEV1 is not an obligate feature of COPD. 
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Chronic obstructive pulmonary dis-ease (COPD) is a major cause of illness and death worldwide.1 Since the research 
by Fletcher and colleagues in the 1970s,2,3 the 
prevailing paradigm of COPD pathogenesis has 
been that, in susceptible persons, exposure to 
particulate matter — especially tobacco smoke 
— leads to clinical disease through acceleration 
of the age-related decline in lung function, as 
assessed by the forced expiratory volume in 1 sec-
ond (FEV1). Subsequent population studies sup-
ported this paradigm and led to therapeutic trials 
aimed at reducing the rapid decline in FEV1.
4-11 
Surprisingly, the observed declines in FEV1 in 
these trials and in observational cohorts of pa-
tients with COPD have been variable and smaller 
than anticipated, particularly among persons 
with the most severe airflow limitation.4-16 These 
observations question the notion that COPD al-
ways follows a trajectory of rapid decline in FEV1 
and are consistent with the hypothesis that low 
maximally attained lung function in early adult-
hood can also result in COPD later in life, even 
when the rate of decline in FEV1 is within the 
normal range.17-21 In fact, this alternative course 
was already suggested by Fletcher and Peto3 and 
emphasized by Burrows et al.22 but was never 
explored in a long-term, prospective investigation. 
We used data from three large cohort studies to 
investigate this issue.
Me thods
Study Design
In this study, we used data from participants in 
three large and independent cohort studies, the 
Framingham Offspring Cohort, the Copenhagen 
City Heart Study, and the Lovelace Smokers Co-
hort. We used FEV1 (≥80% of the predicted value 
[normal FEV1] or <80% of the predicted value 
[low FEV1]) at cohort inception and the presence 
or absence of COPD at the final cohort study visit 
to define four trajectories: normal FEV1 at cohort 
inception and no COPD at the final visit (trajec-
tory 1), low FEV1 at cohort inception and no COPD 
at the final visit (trajectory 2), normal FEV1 at co-
hort inception and COPD at the final visit (trajec-
tory 3), and low FEV1 at cohort inception and COPD 
at the final visit (trajectory 4). We then determined 
the extent to which the rate of decline in FEV1 was 
an explanatory variable for a diagnosis of COPD 
at study end for a patient with a normal initial 
FEV1 or a low initial FEV1 at study inception.
Study Conduct and Oversight
The recruitment of participants and the methods 
used in each of the three cohorts are presented in 
detail in the Supplementary Appendix (available 
with the full text of this article at NEJM.org) and 
are summarized below. Written informed consent 
was obtained from all participants, and the studies 
were approved by the relevant ethics review boards. 
In our analyses, participants were considered to 
have COPD if they had grade 2 or higher COPD 
according to the Global Initiative for Chronic Ob-
structive Lung Disease (GOLD)1 grading system; 
grade 2 or higher COPD according to GOLD is 
defined as a ratio of FEV1 to forced vital capacity 
(FVC) of less than 0.70 and an FEV1 of less than 
80% of the predicted value, with the use of the 
prediction equations from the National Health 
and Nutrition Examination Survey for the Fram-
ingham Offspring Cohort and the Lovelace Smok-
ers Cohort and local prediction equations for the 
Copenhagen City Heart Study.23,24
Framingham Offspring Cohort (FOC)
The FOC as it relates to this study is described in 
detail in the Supplementary Appendix. We iden-
tified 187 current or former smokers, 50 to 65 
years of age, who had GOLD grade 2 or higher 
COPD at the final examination in 1996–1997 and 
who had undergone spirometry before 40 years of 
age. Six of these persons started smoking after 
the study began. We calculated the decline in FEV1 
by measuring the difference (in milliliters) be-
tween the first available spirometric measurement 
and the last measurement obtained at 50 to 65 
years of age and dividing the result by the num-
ber of years between the measurements. The mean 
decline in FEV1 was calculated for persons who 
had had an FEV1 of at least 80% of the predicted 
value on baseline spirometry and for those who 
had had an FEV1 of less than 80% of the pre-
dicted value on baseline spirometry. In addition, 
we identified 1662 persons who underwent the 
first spirometry before 40 years of age, regard-
less of whether they had COPD at the final ex-
amination, and categorized them in one of the 
four trajectories described above.
Copenhagen City Heart Study (CCHS)
The CCHS as it relates to this article is described 
in detail in the Supplementary Appendix. The an-
nualized decline in FEV1 was calculated as the 
slope between two measurements over the longest 
observation period. We identified 145 current or 
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former smokers, 50 to 65 years of age, who had 
GOLD grade 2 or higher COPD at the final ex-
amination in 2001–2003 and who had undergone 
spirometry before 40 years of age. As in the FOC, 
we also identified 1242 participants who were 20 
to 40 years of age at baseline and who underwent 
spirometry 25 years later, regardless of whether 
they had COPD at the final examination, and we 
categorized them in one of the four trajectories 
described above.
Lovelace Smokers Cohort (LSC)
The LSC as it relates to this article is described 
in the Supplementary Appendix. A total of 1553 
persons in the LSC who had undergone at least 
two spirometry tests were included in the current 
analysis. Decline in FEV1 was calculated as the 
slope defined by the first and last data points over 
all visits. For combined analyses with the FOC and 
the CCHS, we identified a subgroup of 163 per-
sons who had similar characteristics to patients 
enrolled in most COPD trials with GOLD grade 2 
or higher COPD and an age of 50 to 65 years at 
the final examination.
Statistical Analysis
We analyzed the combined rate of decline in 
FEV1 among the 495 current or former smokers 
(187 from the FOC, 145 from the CCHS, and 163 
from the LSC) who were 50 to 65 years of age 
and had GOLD grade 2 or higher COPD at the 
final examination. We report the observed de-
cline in FEV1 in subgroups defined according to 
the baseline level of FEV1 and subsequent annu-
alized decline in FEV1. The latter was based on 
prebronchodilator FEV1 values and was calculat-
ed as the absolute difference in milliliters between 
FEV1 values at the two examinations with the 
longest interval between them. We compared the 
proportion of persons with declines in FEV1 of 
more than 1, 2, or 3 standard deviations (z scores) 
above the mean decline among persons who had 
never smoked in the FOC and the CCHS and 
among former smokers in the LSC. The three 
cohorts had different mean declines in FEV1, but 
z scores from each cohort made it possible to 
use a common threshold (e.g., z score >1) to 
define rapid decline in FEV1 in the combined 
analysis. In addition to using z scores, we also 
used threshold values previously reported in the 
literature to classify the decline in FEV1 as 
“rapid” if the annualized average decline was at 
least 40 ml per year and “normal” if the annual-
ized average decline was less than 40 ml per 
year.14,25
We performed a combined analysis of 1622 
participants in the FOC and 1242 participants in 
the CCHS who were younger than 40 years of 
age at baseline and who also underwent spirom-
etry 10 to 27 years after joining their respective 
cohorts. In the main analysis, we defined nor-
mal or low lung function in early adulthood ac-
cording to baseline FEV1 (≥80% or <80% of the 
predicted value). The presence or absence of 
GOLD grade 2 or higher COPD at the final spi-
rometric measurement was the second measure 
used to define the four trajectories. We report 
the distribution of participants in these trajecto-
ries and compared their characteristics and de-
cline in FEV1. Because the assignment to the 
trajectory categories required attendance at the 
first and last examinations, the persons who did 
not attend the last examination, because of death 
or loss to follow-up, could not be included in the 
analysis. We also performed a multivariable lo-
gistic-regression analysis with incident COPD as 
the outcome, as described in detail in the Sup-
plementary Appendix.
To estimate the influence of several potential 
confounders, we performed a number of addi-
tional analyses. First, to estimate a potential 
selection bias, we performed an analysis of hos-
pital admissions for respiratory diseases, admis-
sions for COPD, and survival in the 844 persons 
participating in the CCHS who attended the first 
examination in 1976–1978 but did not attend the 
final examination in 2001–2003 because of death, 
emigration, or loss to follow-up. These persons 
could not be assigned to the trajectory category 
because of the lack of data on final spirometry, 
but they could be categorized according to their 
FEV1 at the baseline examination: less than 80% 
of the predicted value (305) or at least 80% of the 
predicted value (539).
Second, to estimate the way in which regres-
sion to the mean affected the observed declines 
in FEV1, we analyzed the decline in FEV1 in the 
four conceptual trajectory categories using an al-
ternative baseline FEV1 measurement instead of 
the measurement from the first examination, 
which had been used to define these trajectories. 
We used data from 1091 persons in the CCHS 
who, in addition to attending the first examina-
tion (conducted in 1976–1978) and the fourth ex-
amination (conducted in 2001–2003), also attended 
the second examination in 1981–1983. For these 
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persons, we compared the declines between the 
first and fourth examinations (average interval, 
25 years) with those between the second and 
fourth examinations (average interval, 20 years).
Third, we performed a sensitivity analysis 
using two alternative thresholds to define nor-
mal and low maximally attained lung function 
in the FOC and the CCHS (FEV1 ≥85% and <85% 
of the predicted value and FEV1 ≥75% and <75% 
of the predicted value). This analysis investigated 
the effect of the dichotomization on the distri-
bution of participants in the various trajectories.
R esult s
Characteristics of the Participants  
in the Three Cohorts
At cohort inception, LSC participants were, on 
average, 20 years older than the participants in 
the the FOC and the CCHS (Table 1). In all the 
cohorts, regardless of the initial FEV1, the annual 
decline in FEV1 was steepest among persons in 
whom COPD developed. The highest absolute 
declines were observed in the CCHS and in the 
LSC, but when the declines in FEV1 were com-
pared according to the z scores within each co-
hort, the persons in the CCHS and the FOC had 
the greatest declines, a finding that is compatible 
with the high prevalence of continuous smoking 
in these cohorts.
Rate of Decline in FEV1 among Persons  
in Whom COPD Developed
Table 2 shows the characteristics of the partici-
pants who had ever smoked and who had GOLD 
grade 2 or higher COPD and were 50 to 65 years 
of age at the final examination, stratified ac-
cording to their baseline FEV1 (percentage of the 
predicted value). The baseline FEV1 was at least 
80% of the predicted value in 20% of the LSC 
participants, in 44% of the FOC participants, in 
49% of the CCHS participants, and in 38% of the 
participants in the three cohorts combined. In 
all the cohorts, participants with a baseline FEV1 
of less than 80% of the predicted value had had 
a slightly higher cumulative exposure to tobacco 
before the baseline examination than those with 
an FEV1 above that threshold, but this difference 
was not significant. Among persons with COPD 
at the final examination, the observed decline 
in FEV1 and the proportion with a rapid decline 
in FEV1 (defined as >2 or >3 SD [z score >2 or 
z score >3]) were significantly greater among 
participants with a baseline FEV1 of at least 80% 
of the predicted value than among those with a 
lower baseline FEV1 (Table 2). The results of the 
multivariable logistic-regression analysis with 
incident COPD at the final examination as the 
main outcome are presented in Tables S1 and S2 
in the Supplementary Appendix.
FEV1 Trajectories
Table 3 shows the distribution in the four FEV1 
trajectory categories of the 1622 participants in 
the FOC and the 1242 participants in the CCHS 
who underwent spirometry before 40 years of 
age. Continuous smoking and an early age at the 
start of smoking were significantly more preva-
lent among the participants in the trajectories 
leading to COPD (trajectory 3 and trajectory 4) 
than among the participants in the trajectories 
not leading to COPD (trajectory 1 and trajectory 
2). After an average observation time of 22 years, 
332 persons — 12% of the 2864 participants 
included in this analysis — had airflow limita-
tion fulfilling the criterion of GOLD grade 2 or 
higher COPD. Of these 332 persons with COPD, 
158 had had normal baseline FEV1, which con-
stitutes 7% of the 2207 persons with normal 
FEV1 at baseline, whereas 174 had had low base-
line FEV1, which constitutes 26% of the 657 
persons with low baseline FEV1 (P<0.001 for the 
comparison between participants with an FEV1 
≥80% of the predicted value at baseline and 
those with an FEV1 <80% of the predicted value). 
Thus, 48% of the 332 persons with COPD at the 
final examination followed the trajectory from 
normal baseline FEV1 to COPD, with an average 
decline in FEV1 of 53 ml per year (trajectory 3 in 
Table 3, and Fig. S4 in the Supplementary Ap-
pendix), whereas 52% followed the FEV1 trajec-
tory from low maximally attained lung function 
(FEV1 <80%) at baseline to COPD, with a sig-
nificantly smaller decline in FEV1 of 27 ml per 
year (P<0.001) (trajectory 4 in Table 3, and Fig. 
S4 in the Supplementary Appendix). As seen in 
Figure 1, the distribution of the observed de-
clines in FEV1 in the four trajectory categories 
showed substantial variability and overlap.
Among the 2864 participants in the FOC and 
the CCHS who underwent spirometry before 40 
years of age, 812 reported at both the baseline 
examination and the final examination that they 
had never smoked. The average decline in FEV1 
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Characteristic Lovelace Smokers Cohort Framingham Offspring Cohort Copenhagen City Heart Study
Participants with 
COPD at Final 
Examination 
(N = 163)
All Participants 
Included in 
Analyses 
(N = 1553)
Participants with 
COPD at Final 
Examination 
(N = 187)
All Participants 
Included in 
Analyses 
(N = 1622)
Participants with 
COPD at Final 
Examination 
(N = 145)
All Participants 
Included in 
Analyses 
(N = 1242)
At baseline examination
Male sex — no. (%) 39 (24) 336 (22) 97 (52) 765 (47) 83 (57) 587 (47)
Age — yr
Mean 56±5 56±9 34±4 33±4 36±4 33±5
Range 41–64 31–75 25–40 24–40 25–40 21–40
FEV1
Mean — liters 2.0±0.6 2.5±0.8 2.9±0.7 3.3±0.8 3.1±0.8 3.4±0.9
% of predicted value 66±17 85±19 77±13 89±13 79±15 88±14
Smoking history — pack-yr 49±22 40±21 20±11 16±12 17±9 8±10
Current smoker — no./total 
no. (%)
104/163 (64) 847/1553 (55) 157/187 (84) 714/1618 (44) 139/144 (97) 697/1239 (56)
FEV1:FVC
Mean — % 62±5 72±10 81±10 86±9 78±10 83±9
<0.70 — no. (%) 116 (71) 318 (20) 24 (13) 78 (5) 25 (17) 68 (5)
At final examination
Duration of follow-up — yr
Mean 4±2 5±2 21±2 21±2 23±4 25±0.4
Range 1–10 1–10 10–27 10–27 14–27 24–27
FEV1
Mean — liters 1.8±0.6 2.5±0.8 2.2±0.5 2.9±0.7 1.9±0.6 2.8±0.8
% of predicted value 63±16 87±20 68±11 91±15 62±15 92±18
Smoking history — pack-yr 49±22 40±21 34±20 24±19 42±21 21±24
Current smoker — no./total 
no. (%)
35/163 (21) 174/1553 (11) 87/187 (47) 321/1622 (20) 107/142 (75) 448/1220 (37)
FEV1:FVC
Mean — % 56±10 68±11 63±7 74±7 62±8 76±7
<0.70 — no. (%) 163 (100) 383 (25) 187 (100) 377 (23) 145 (100) 202 (16)
Decline in FEV1
Mean — ml/yr 51±146 19±97 34±22 20±20 51±29 25±23
≥40 ml/yr — no. (%) 81 (50) 476 (31) 60 (32) 180 (11) 95 (66) 258 (21)
z score — no. (%)†
>1 32 (20) 168 (11) 73 (39) 254 (16) 99 (68) 279 (22)
>2 15 (9) 55 (4) 29 (16) 53 (3) 55 (38) 90 (7)
>3 6 (4) 26 (2) 8 (4) 11 (1) 23 (16) 26 (2)
*  Plus–minus values are means ±SD. Chronic obstructive pulmonary disease (COPD) was defined according to the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD)1 grading system as grade 2 or higher COPD (a ratio of forced expiratory volume in 1 second 
[FEV1] to forced vital capacity [FVC] of <0.70 and an FEV1 of <80% of the predicted value, with the use of the prediction equations from the 
National Health and Nutrition Examination Survey for the Lovelace Smokers Cohort and the Framingham Offspring Cohort and local predic-
tion equations for the Copenhagen City Heart Study23,24).
†  The z scores are defined according to internal controls in each cohort and describe the decline in FEV1 1, 2, and 3 standard deviations 
above the observed mean decline among former smokers in the Lovelace Smokers Cohort and among those who have never smoked in the 
Framingham Offspring Cohort and the Copenhagen City Heart Study.
Table 1. Characteristics of Participants 50 to 65 Years of Age with COPD at the Final Examination and All Participants with at Least Two FEV1 
Measurements in the Three Cohorts.*
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among these participants was 18 ml per year. 
Only 27 of them had COPD at the final examina-
tion, which constitutes 8% of all persons with 
COPD. Of the persons who had never smoked 
and who had COPD at the last study visit, 7 (26%) 
followed trajectory 3, whereas 20 (74%) followed 
the trajectory from low maximally attained lung 
function (FEV1 <80%) at baseline to COPD (tra-
jectory 4). The average decline in FEV1 among 
these persons was 37 ml per year and 23 ml per 
year, respectively.
The analysis of persons who attended the 
baseline examination of the CCHS but not the 
final examination showed that participants with 
an FEV1 of less than 80% of the predicted value 
had a significantly greater risk of hospital ad-
missions for respiratory diseases than did those 
with an FEV1 of at least 80% of the predicted 
value (25% vs. 18%, P = 0.02), as well as a sig-
nificantly greater corresponding risk of admis-
sions for COPD (9% vs. 4%, P = 0.008) and of 
death (32% vs. 25%, P = 0.02). Additional analy-
ses of the decline in FEV1 among those who did 
not attend the final, fourth examination of the 
CCHS showed a greater decline in FEV1 in this 
group between the first and the second exami-
nation and between the first and the third ex-
amination than in the group of participants who 
attended the fourth examination (Table S3 in the 
Supplementary Appendix).
Analysis of the decline in FEV1 between the 
second and the fourth examination of the CCHS 
(average interval, 20 years) that was conducted to 
investigate the effect of regression toward the 
mean showed a significantly greater decline in 
FEV1 among the persons in trajectory 3 than 
among those in trajectory 4 (decline of 60 ml per 
year in trajectory 3 vs. 37 ml per year in trajec-
tory 4, P<0.001) (Table S4 in the Supplementary 
Appendix). A corresponding analysis of the de-
cline in FEV1 between the second and the third 
examination (average interval, 11 years) showed 
a similar pattern, with a greater decline among 
those in trajectory 3 than among those in trajec-
tory 4, but the difference between these two 
declines was not significant (27 ml per year and 
17 ml per year, respectively; P = 0.37).
Finally, we observed that the choice of the 
threshold value defining a normal FEV1 level at 
the first examination of the FOC and the CCHS 
substantially affected the distribution of the par-
ticipants in the two trajectory categories leading 
to COPD. When we used a cutoff value of 85% of 
the predicted FEV1 to define a normal FEV1 in 
early adulthood, we found that 232 of the 332 
participants (70%) who presented with COPD at 
the final examination were considered to be in the 
trajectory 4 category (low maximally attained 
lung function at baseline and COPD at final ex-
amination). In contrast, when we used a cutoff 
value of 75% of the predicted FEV1 to define a 
normal FEV1, only 126 of the 332 persons (38%) 
with COPD could be assigned to trajectory 4.
Discussion
The main new finding of this study is that the 
lung-function value reached in early adulthood 
seems to be important with respect to the diag-
nosis of COPD later in life. Our data suggest that 
approximately half the persons presenting with 
airflow limitation followed the paradigm that 
implied a rapid decline in FEV1 from a normal 
level of lung function in early adulthood, where-
as the other half had a rather normal decline in 
FEV1 but started from a low initial value of FEV1.
We acknowledge that dichotomizing persons 
with COPD into two specific trajectories, al-
though conceptually helpful for understanding 
the natural history of the disease, is artificial. 
Instead, there exists a wide range of individual 
trajectories, such that both low maximally attained 
lung function in early adulthood and a subsequent 
rapid decline may contribute to COPD.21 In addi-
tion, it is possible that a single person over time 
can have periods of rapid decline in FEV1 fol-
lowed by periods when the decline is normal or 
almost normal. If the period of fast decline had 
already taken place in early adulthood, this per-
son would have been wrongly assigned to the 
trajectory category of low maximally attained 
lung function (trajectory 4) in our study, even 
though a rapid decline in FEV1 was the main 
mechanism behind this person’s COPD. In addi-
tion, our sensitivity analyses showed that the 
estimation of the contribution of these two con-
ceptual trajectories was strongly affected by the 
cutoff values chosen for the definition of a nor-
mal maximally attained FEV1. Nevertheless, even 
though we cannot precisely estimate the contri-
bution of the trajectory of low maximally at-
tained lung function (trajectory 4 in Fig. 1) to 
COPD using our study design, our results sug-
gest that this contribution may be substantial 
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and that populations of patients with COPD com-
prise persons with different rates of decline in 
FEV1 (Fig. 1). This observation is in accord with 
previous studies and suggests that a substantial 
proportion of patients with COPD may not have 
had a rapid decline in FEV1, which for decades has 
been regarded as the hallmark of COPD.2,3,12-14
Persons with a baseline FEV1 of less than 80% 
of the predicted value had a risk of COPD in 
midlife that was more than 3 times as high as the 
risk among those with a higher baseline FEV1 (26% 
vs. 7%). Studies involving children and young 
adults have shown that the most important de-
terminant of maximally attained lung function 
later in life was the lung-function value at a 
younger age.26-29 Svanes et al. observed that child-
hood risk factors such as maternal smoking, 
childhood respiratory infections, and childhood 
asthma were strongly related to the development 
of COPD in young adults.30 Nevertheless, although 
our results highlight the important role of maxi-
mally attained lung function in early adulthood, 
Figure 1. Distribution of the Declines in FEV1 in the Four Lung-Function Trajectories.
Shown is the distribution of observed annual decline in forced expiratory volume in 1 second (FEV1) among 2864 
participants in the Framingham Offspring Cohort (FOC) and the Copenhagen City Heart Study (CCHS), according 
to the four trajectories defined on the basis of a normal FEV1 (≥80% of the predicted value) or low FEV1 (<80% of 
the predicted value) at baseline and the presence or absence of chronic obstructive pulmonary disease (COPD) at the 
final examination. Participants were considered to have COPD if they had grade 2 or higher COPD according to the 
Global Initiative for Chronic Obstructive Lung Disease (GOLD)1 grading system; grade 2 or higher COPD according 
to GOLD is defined as a ratio of FEV1 to forced vital capacity of less than 0.70 and an FEV1 of less than 80% of the 
predicted value, with the use of the prediction equations from the National Health and Nutrition Examination Sur-
vey for the FOC and local prediction equations for the CCHS.23,24 The mean decline in FEV1 was 24 ml per year in 
trajectory 1 (Panel A), 2 ml per year in trajectory 2 (Panel B), 53 ml per year in trajectory 3 (Panel C), and 27 ml  
per year in trajectory 4 (Panel D). The decline in FEV1 in trajectory 3 was considered to be rapid.
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they also indicate that COPD does not develop in 
approximately 75% of persons with a low maxi-
mally attained FEV1.
Our study has a number of strengths and 
limitations. Among the former is the replication 
of findings in large and independent cohorts. 
The long observation periods in the FOC and the 
CCHS, as compared with the shorter observation 
periods in other studies, allowed robust esti-
mates of FEV1, because the annual decline in 
FEV1 was small relative to the high measurement 
error in the assessment of FEV1.
13,31
The two major potential limitations of our 
study are the selection bias and the regression to 
the mean for the estimates of decline in FEV1. 
The long observation period in the FOC and the 
CCHS introduced a selection of healthy persons, 
which may have resulted in underestimation of 
lung-function decline. In line with this, we ob-
served that the persons who did not attend the 
final, fourth examination of the CCHS, because 
of either death or loss to follow-up, had a great-
er decline in FEV1 between the first and the 
second examination and between the first and 
the third examination than did the persons who 
attended the fourth examination (Table S3 in the 
Supplementary Appendix). Previous analyses of 
the CCHS indicated that a rapid decline in FEV1 
was associated with higher mortality.32 However, 
because the persons included in the FOC and 
CCHS analyses were quite young at baseline, this 
survivor bias is likely to be smaller than that in 
most COPD intervention trials, which have en-
rolled much older patients.12,13
The use of baseline FEV1 measurement both 
to classify the participants as having a normal or 
low initial FEV1 value and to estimate the subse-
quent decline in FEV1 introduced potential prob-
lems with respect to regression to the mean.33 
Persons with a higher initial FEV1 would tend to 
have a more rapid observed decline in FEV1 even 
if there was no association between these two. 
In contrast, among persons with a low initial 
FEV1, regression to the mean would lead to a 
small decline in FEV1. Therefore, it would have 
been preferable to perform multiple FEV1 mea-
surements at the beginning of the studies to 
define the true FEV1 baseline more precisely, as 
is often done in interventional trials, but we did 
not have such data. Although regression to the 
mean undoubtedly affects our findings, the anal-
yses of decline in FEV1 starting from the second 
rather than the first examination of the CCHS 
showed a consistent pattern of a greater decline 
among persons in trajectory 3 than among those 
in trajectory 4 (Table S4 in the Supplementary Ap-
pendix). This supports our main conclusions and 
indicates that regression to the mean is not the 
only mechanism responsible for our findings.
Still another potential methodologic weak-
ness of the FOC and the CCHS concerns the age 
of the participants at baseline (approximately 35 
years). Although this age corresponds to the last 
part of the “plateau phase” of FEV1 (i.e., the age 
at which maximum lung function is attained 
before the inevitable decline with aging begins 
to take place), it would have been preferable if 
the participants had undergone spirometry in 
their mid-20s, so that the potential influence of 
an incipient decline in FEV1 during early adult-
hood could be avoided.34-37
Finally, the appropriateness of the nomencla-
ture used in the present article (i.e., COPD or no 
COPD) could be misleading, because not all peo-
ple with a ratio of FEV1 to FVC of less than 0.70 
and an FEV1 of less than 80% of the predicted 
value have COPD. We chose the term COPD be-
cause it is in common use, but the broader de-
scriptive term “airflow limitation” could be con-
sidered by some to be more correct.
In conclusion, the results of this study sug-
gest that the classic trajectory of an accelerated 
decline in FEV1 from a normal level is not an 
obligate feature of COPD and that a substantial 
proportion of the persons in whom COPD develops 
have a low FEV1 level in early adulthood.
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